In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
In the latest session, PTC Therapeutics Inc (NASDAQ: PTCT) closed at $34.16 up 6.25% from its previous closing price of $32.15. In other words, the price has increased by $6.25 from its previous closing price. On the day, 1.1 million shares were traded. PTCT stock price reached its highest trading level at $35.47 during the session, while it also had its lowest trading level at $31.7.
Ratios:
For a deeper understanding of PTC Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.98 and its Current Ratio is at 2.03.
On December 08, 2023, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $37.
Oppenheimer Upgraded its Perform to Outperform on October 30, 2023, while the target price for the stock was maintained at $165.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 19 ’24 when Klein Matthew B. sold 3,361 shares for $24.89 per share. The transaction valued at 83,669 led to the insider holds 225,807 shares of the business.
Klein Matthew B. sold 1,307 shares of PTCT for $32,851 on Apr 17 ’24. The CHIEF EXECUTIVE OFFICER now owns 229,168 shares after completing the transaction at $25.14 per share. On Apr 17 ’24, another insider, Pauwels Eric, who serves as the CHIEF EXECUTIVE OFFICER of the company, sold 787 shares for $25.14 each. As a result, the insider received 19,781 and left with 67,694 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTCT now has a Market Capitalization of 2619962624 and an Enterprise Value of 3995525120. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.82. Its current Enterprise Value per Revenue stands at 4.308 whereas that against EBITDA is -130.658.
Stock Price History:
The Beta on a monthly basis for PTCT is 0.63, which has changed by -0.3884712 over the last 52 weeks, in comparison to a change of 0.23568535 over the same period for the S&P500. Over the past 52 weeks, PTCT has reached a high of $59.84, while it has fallen to a 52-week low of $17.53. The 50-Day Moving Average of the stock is 20.54%, while the 200-Day Moving Average is calculated to be 19.37%.
Shares Statistics:
For the past three months, PTCT has traded an average of 903.73K shares per day and 1376210 over the past ten days. A total of 75.71M shares are outstanding, with a floating share count of 73.80M. Insiders hold about 3.78% of the company’s shares, while institutions hold 110.06% stake in the company. Shares short for PTCT as of 1713139200 were 10204235 with a Short Ratio of 11.29, compared to 1710460800 on 10889756. Therefore, it implies a Short% of Shares Outstanding of 10204235 and a Short% of Float of 17.950001.
Earnings Estimates
As of right now, 13.0 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$1.25 for the current quarter, with a high estimate of -$0.98 and a low estimate of -$1.87, while EPS last year was -$2.66. The consensus estimate for the next quarter is -$1.68, with high estimates of -$1.1 and low estimates of -$2.28.
Analysts are recommending an EPS of between -$2.88 and -$7.94 for the fiscal current year, implying an average EPS of -$5.72. EPS for the following year is -$4.31, with 14.0 analysts recommending between $0.8 and -$7.46.
Revenue Estimates
A total of 11 analysts believe the company’s revenue will be $159.02M this quarter.It ranges from a high estimate of $186.11M to a low estimate of $112.1M. As of the current estimate, PTC Therapeutics Inc’s year-ago sales were $213.81MFor the next quarter, 11 analysts are estimating revenue of $142.33M. There is a high estimate of $164M for the next quarter, whereas the lowest estimate is $106.6M.
A total of 14 analysts have provided revenue estimates for PTCT’s current fiscal year. The highest revenue estimate was $845.4M, while the lowest revenue estimate was $539M, resulting in an average revenue estimate of $663.93M. In the same quarter a year ago, actual revenue was $937.82MBased on 14 analysts’ estimates, the company’s revenue will be $662.58M in the next fiscal year. The high estimate is $872.2M and the low estimate is $350M.
